These results indicate that the pharmacological rescue of abnormal synaptic morphology and behavior in the adult ATR-X mouse model and identified postnatal Sig-1R activation as a potential therapeutic strategy for countering the various debilitating symptoms of intellectual disability, including those of ATR-X syndrome. Here, SIGMAR1 is linked to Alpha-thalassemia - X-linked intellectual disability syndrome.